Identification and characterization of the NMYC gene product in human neuroblastoma cells by monoclonal antibodies with defined specificities.
Increased N-myc (now designated NMYC in human gene nomenclature) gene expression has been detected at the transcriptional level in certain types of neoplasms. As yet, the N-myc gene product has not been identified. To detect and characterize the N-myc gene product, we have developed monoclonal antibodies against the putative N-myc gene product made in Escherichia coli as a fusion protein. The antibodies that recognize the N-myc-specific regions were selected on the basis of their reactivities to different portions of the fusion protein. These monoclonal antibodies detect a pair of closely migrating polypeptides of 60 and 63 kDa in nuclear fractions of human neuroblastoma cells. The relative levels of the polypeptides are roughly proportional to the level of N-myc transcripts present in a panel of neuroblastoma lines. These two polypeptides have a half-life of approximately equal to 35 min, and they are indistinguishable from each other by their epitopic profiles.
D000911:Antibodies, Monoclonal; D002460:Cell Line; D002467:Cell Nucleus / Q000032:analysis; D000939:Epitopes / Q000032:analysis; D004926:Escherichia coli / Q000235:genetics; D006801:Humans; D008970:Molecular Weight; D009447:Neuroblastoma / Q000235:genetics*; D009857:Oncogenes; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016271:Proto-Oncogene Proteins c-myc; D014158:Transcription, Genetic
D000911:Antibodies, Monoclonal; D000939:Epitopes; D011518:Proto-Oncogene Proteins; D016271:Proto-Oncogene Proteins c-myc